IPILIMUMABの臨床試験（NIH ClinicalTrials.govデータベースの検索結果）

IPILIMUMAB（MDX-010）で臨床試験のデータベースNIH ClinicalTrials.govを検索した結果です（2019年11月3日検索）

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery (Phase 1) NCT00025181
Novel Adjuvants for Peptide-Based Melanoma Vaccines (Phase 1) NCT00028431
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma (Phase 2) NCT00032045
Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer (Phase 1) NCT00039091
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy (Phase 1) NCT00047164
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma (Phase 2) NCT00050102
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer (Phase 2) NCT00050596
Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer (Phase 2) NCT00057889
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT00058279
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer (Phase 1) NCT00060372
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer (Phase 1) NCT00064129
CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer (Phase 1|Phase 2) NCT00075192
Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma (Phase 2) NCT00077532
Study of MDX-010 in Stage IV Breast Cancer (Phase 2) NCT00083278
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma (Phase 2) NCT00084656
CP-675,206 In Patients With Advanced Melanoma (Phase 2) NCT00086489
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma (Phase 1|Phase 2) NCT00089076
CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery (Phase 1) NCT00090896
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma (Phase 3) NCT00094653
MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery (Phase 2) NCT00112580
Vaccine and Antibody Treatment of Prostate Cancer (Phase 1) NCT00113984
A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide (Phase 2) NCT00135408
A Study of Anti-CTLA4 Antibody in People With Advanced Synovial Sarcoma (Phase 2) NCT00140855
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies (Phase 2) NCT00162123
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer (Phase 2) NCT00170157
Study of CP-675,206 in Refractory Melanoma (Phase 2) NCT00254579
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy (Phase 3) NCT00257205
Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010) (Phase 1|Phase 2) NCT00261365
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma (Phase 2) NCT00289627
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma (Phase 2) NCT00289640
Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC) (Phase 2) NCT00312975
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer (Phase 1|Phase 2) NCT00323882
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma (Phase 3) NCT00324155
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma (Phase 2) NCT00357461
Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection (Phase 1) NCT00362713
Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma (Phase 1) NCT00372853
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued. (Phase 2) NCT00378482
Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody (Phase 1) NCT00431275
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma (Phase 2) NCT00471887
Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients (Phase 2) NCT00488995
Compassionate Use Trial for Unresectable Melanoma With Ipilimumab () NCT00495066
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) (Phase 2) NCT00527735
A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer (Phase 1) NCT00556023
Treatment Use Study for Advanced Melanoma. () NCT00584493
A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma (Phase 1) NCT00585000
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin’s Lymphoma, ALL & CLL (Phase 1) NCT00586391
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases (Phase 2) NCT00623766
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma (Phase 3) NCT00636168
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma (Not Applicable) NCT00685750
CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer (Phase 1) NCT00702923
Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (Phase 1) NCT00729950
Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia (Phase 1) NCT00732186
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma (Phase 1) NCT00790010
Drug-Drug Interaction – 3 Arm – Carboplatin/Paclitaxel, Dacarbazine (Phase 1) NCT00796991
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma (Phase 1) NCT00803374
Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer (Phase 1) NCT00836407
Study of Immunotherapy to Treat Advanced Prostate Cancer (Phase 3) NCT00861614
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT00871481
Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer (Phase 1) NCT00880854
Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma (Phase 1) NCT00920907
Long-term Data Collection for Subjects in MDX-010 Studies () NCT00928031
Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma (Early Phase 1) NCT00972933
Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma (Phase 2) NCT01008358
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (Phase 1) NCT01024231
Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma (Phase 2) NCT01034787
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer (Phase 3) NCT01057810
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma (Phase 1) NCT01103635
Ipilimumab + Temozolomide in Metastatic Melanoma (Phase 2) NCT01119508
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (Phase 2) NCT01134614
Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer (Phase 1) NCT01165216
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma (Phase 1) NCT01176474
Neoadjuvant Ipilimumab in Prostate Cancer (Phase 2) NCT01194271
Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 (Phase 2) NCT01216696
Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma (Phase 1) NCT01245556
Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer (Phase 1) NCT01255800
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery (Phase 3) NCT01274338
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin (Phase 3) NCT01285609
Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (Phase 1) NCT01295827
Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma (Phase 2) NCT01302496
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity (Phase 2) NCT01323517
The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer (Phase 2) NCT01331525
Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients (Phase 1) NCT01334099
THE IPI – Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease (Phase 2) NCT01355120
Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma (Phase 2) NCT01363206
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer (Phase 2) NCT01377389
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) (Phase 1) NCT01400451
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma (Phase 1) NCT01409174
IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma (Phase 1|Phase 2) NCT01409187
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer (Phase 1) NCT01445379
Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy (Phase 2) NCT01449279
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone (Phase 3) NCT01450761
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) (Phase 1) NCT01454102
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer (Phase 2) NCT01471197
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) (Phase 1) NCT01472081
Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery (Phase 1) NCT01473940
A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 (Phase 2) NCT01480323
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma (Phase 1) NCT01489059
Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim () NCT01489423
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma (Phase 2) NCT01495988
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma (Phase 1) NCT01496807
RADVAX邃｢: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA (Phase 1|Phase 2) NCT01497808
Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (Phase 2) NCT01498978
Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer (Phase 1) NCT01502592
Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer (Phase 1) NCT01510288
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma () NCT01511913
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab (Phase 3) NCT01515189
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma (Phase 2) NCT01524991
Ipilimumab and GMCSF Immunotherapy for Prostate Cancer (Phase 2) NCT01530984
Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma (Phase 1) NCT01557114
Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma (Phase 2) NCT01565837
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma (Phase 2) NCT01585194
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy (Phase 2) NCT01585987
Doxycycline, Temozolomide and Ipilimumab in Melanoma (Phase 1|Phase 2) NCT01590082
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma (Phase 1|Phase 2) NCT01592370
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Phase 1|Phase 2) NCT01604889
Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-ﾎｱ2b for Melanoma (Phase 1) NCT01608594
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer (Phase 2) NCT01611558
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (Phase 1) NCT01621490
Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic (Phase 1) NCT01643278
A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma (Phase 2) NCT01654692
An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (Phase 1|Phase 2) NCT01658878
A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma (Phase 1) NCT01672450
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma (Phase 2) NCT01673854
Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma (Phase 2) NCT01676649
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma (Phase 2) NCT01681212
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naﾃｯve Patients With Progressive Metastatic Castration-resistant Prostate Cancer (Phase 1|Phase 2) NCT01688492
Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT01689870
Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma (Phase 2) NCT01689974
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer (Phase 2) NCT01693783
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma (Phase 2) NCT01696045
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts (Not Applicable) NCT01701674
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma (Phase 1) NCT01703507
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (Phase 2) NCT01708941
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma (Phase 2) NCT01709162
Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer (Phase 1) NCT01711515
A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors (Phase 1|Phase 2) NCT01714739
Study of Ipilimumab in the Immune System (Not Applicable) NCT01715077
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (Phase 1) NCT01729806
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases (Early Phase 1) NCT01730157
Ipilimumab and Imatinib Mesylate in Advanced Cancer (Phase 1) NCT01738139
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (Phase 1|Phase 2) NCT01740297
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma (Phase 2) NCT01740401
Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma (Phase 1|Phase 2) NCT01743157
Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor (Phase 1) NCT01750580
Ipilimumab and Lenalidomide in Advanced Cancer (Phase 1) NCT01750983
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (Phase 1) NCT01757639
Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities () NCT01758575
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma (Phase 1) NCT01767454
Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer (Phase 1|Phase 2) NCT01769222
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) (Phase 2) NCT01783938
Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy (Early Phase 1) NCT01789827
Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer (Phase 2) NCT01804465
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma (Phase 1) NCT01810016
Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) (Phase 2) NCT01820754
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant (Phase 1) NCT01822509
Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma (Phase 2) NCT01827111
Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer (Phase 1) NCT01832870
Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma (Phase 1) NCT01838200
Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma (Phase 2) NCT01840007
Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) (Phase 1) NCT01840579
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) (Phase 3) NCT01844505
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma (Phase 4) NCT01856023
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) (Phase 3) NCT01866319
A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer (Phase 2) NCT01896869
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (Phase 1|Phase 2) NCT01896999
Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma (Phase 2) NCT01913691
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies (Phase 2) NCT01919619
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (Phase 2) NCT01927419
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (Phase 1|Phase 2) NCT01928394
Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer (Phase 1) NCT01935921
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery (Phase 1) NCT01940809
SRS (Stereotactic Radiosurgery) Plus Ipilimumab (Phase 1) NCT01950195
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (Phase 2) NCT01950390
Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma (Phase 2) NCT01970527
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized “Proof-of-principle” Phase II Study (Phase 2) NCT01973322
MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma (Phase 2) NCT01973608
A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients (Phase 1) NCT01984255
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab (Phase 1) NCT01986426
Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients (Phase 2) NCT01988077
Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients (Phase 2) NCT01990859
A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma (Phase 1) NCT01996202
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer (Phase 1) NCT01998126
Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox (Phase 2) NCT02009384
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients (Phase 1|Phase 2) NCT02009397
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (Phase 3) NCT02017717
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy (Phase 2) NCT02020070
Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 (Phase 2) NCT02027935
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma (Phase 1) NCT02032810
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) (Phase 1|Phase 2) NCT02039674
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease (Phase 2) NCT02046733
Ipilimumab 12-month Intensive Pharmacovigilance Protocol () NCT02050594
Immunotherapy Study for Patients With Stage IV Melanoma (Phase 2) NCT02054520
An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread (Phase 2) NCT02060188
A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. (Phase 4) NCT02068196
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies (Phase 1) NCT02070406
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT02073123
Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma (Phase 1) NCT02077114
Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030) () NCT02083484
Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) (Phase 1|Phase 2) NCT02089685
Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma (Phase 2) NCT02094391
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery (Phase 2) NCT02097732
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma (Phase 2) NCT02107755
T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer (Early Phase 1) NCT02113657
GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases (Phase 2) NCT02115139
Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma (Phase 1) NCT02115243
Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma (Phase 1) NCT02117362
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer (Phase 2|Phase 3) NCT02154490
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery (Phase 2) NCT02158520
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors (Phase 1) NCT02174172
Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma () NCT02186249
Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation (Phase 2) NCT02196961
Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma (Phase 1) NCT02200562
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery (Phase 2) NCT02203604
Adoptive Therapy Using Antigen-Specific CD4 T-Cells (Phase 1) NCT02210104
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery (Early Phase 1) NCT02210117
Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) (Phase 2) NCT02221739
YERVOYﾂｮ Risk Minimization Tool Effectiveness Evaluation Survey () NCT02224768
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (Phase 3) NCT02224781
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) (Phase 3) NCT02231749
Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors (Phase 1|Phase 2) NCT02239900
A Phase I/II Study of Intratumoral Injection of SD-101 (Phase 1|Phase 2) NCT02254772
RTA 408 Capsules in Patients With Melanoma – REVEAL (Phase 1|Phase 2) NCT02259231
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC (Phase 2) NCT02259621
A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma (Phase 2) NCT02272855
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma (Phase 1|Phase 2) NCT02275416
Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma (Phase 3) NCT02278887
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin (Phase 3) NCT02279732
Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive (Phase 2) NCT02279862
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (Phase 1|Phase 2) NCT02304458
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma (Phase 2) NCT02306850
Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) (Phase 1) NCT02307149
Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma (Phase 1) NCT02311920
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer (Phase 2) NCT02314169
An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself (Phase 2) NCT02320058
Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (Phase 2|Phase 3) NCT02339571
Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs (Phase 2) NCT02350764
Anti窶娠D 1 Brain Collaboration for Patients With Melanoma Brain Metastases (Phase 2) NCT02374242
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer (Phase 1) NCT02381314
A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma (Phase 1|Phase 2) NCT02385669
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238) (Phase 3) NCT02388906
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia (Phase 2) NCT02397720
Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan () NCT02402699
Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma (Phase 2) NCT02403778
Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma (Phase 1) NCT02406183
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (Phase 1) NCT02408861
A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma (Phase 1|Phase 2) NCT02413827
Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer (Phase 1) NCT02423928
Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma (Phase 2) NCT02428192
Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (Phase 1) NCT02437279
Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy () NCT02449837
Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma (Phase 1|Phase 2) NCT02452281
Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER) (Phase 2) NCT02452294
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer (Phase 1) NCT02453620
A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis (Phase 3) NCT02460068
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers (Phase 1|Phase 2) NCT02467361
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer (Phase 1) NCT02475213
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (Phase 3) NCT02477826
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (Phase 1|Phase 2) NCT02488759
PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma () NCT02492815
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (Phase 1) NCT02496208
Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (Phase 2) NCT02498600
Cytokine-induced Killer Study for Patients With Stage II Melanoma (Phase 2) NCT02498756
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery (Phase 2) NCT02500797
Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer (Phase 2) NCT02506114
High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (Phase 3) NCT02506153
A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors (Phase 1) NCT02516527
Nivolumab With or Without Ipilimumab or Relatlimab Before Surgery in Treating Patients With Stage IIIB-IV Melanoma That Can Be Removed by Surgery (Phase 2) NCT02519322
Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED (Phase 2) NCT02523313
Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS) (Phase 2) NCT02530463
MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer (Phase 2) NCT02536794
An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy (Phase 3) NCT02538666
A Comparative Study in Chinese Subjects With Chemotherapy Naﾃｯve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine (Phase 3) NCT02545075
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) (Phase 2) NCT02553642
Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy () NCT02581228
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma (Phase 3) NCT02599402
Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy. () NCT02600143
Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 (Phase 2) NCT02601014
A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients (Phase 1) NCT02608437
Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases (Phase 2) NCT02621515
Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer (Not Applicable) NCT02626130
Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma (Phase 2) NCT02626962
Sequential Combo Immuno and Target Therapy (SECOMBIT) Study (Phase 2) NCT02631447
A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT02644967
An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma (Phase 2) NCT02648997
BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial (Phase 2) NCT02656706
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread (Phase 1|Phase 2) NCT02658890
Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (Phase 2) NCT02659059
A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma (Phase 1) NCT02659540
Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases (Phase 2) NCT02662725
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies (Phase 1) NCT02668770
Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas (Phase 1) NCT02675439
Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (Phase 1|Phase 2) NCT02681302
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (Phase 2) NCT02693535
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer (Phase 1|Phase 2) NCT02696993
RATIO: Rational Approach To Immuno-Oncology (Not Applicable) NCT02700971
Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer (Phase 2) NCT02701400
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (Phase 2) NCT02703623
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma (Phase 3) NCT02714218
Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients (Phase 2) NCT02716272
Yervoyﾂｮ Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma () NCT02717364
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma (Phase 1) NCT02723006
Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy (Phase 2) NCT02731729
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone (Phase 1|Phase 2) NCT02736123
An Investigational Immuno-therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Patients With Solid Cancers That Are Advanced or Have Spread (Phase 1|Phase 2) NCT02737475
Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases () NCT02739386
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (Phase 3) NCT02741570
Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma (Phase 2) NCT02743819
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (Phase 2) NCT02750514
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery (Phase 1) NCT02754856
Ipilimumab-induced Lung Toxicity: Observational Study () NCT02755233
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo (Phase 2) NCT02763761
Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study () NCT02780089
GI Complications in Cancer Immunotherapy Patients () NCT02784366
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Phase 3) NCT02785952
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma (Phase 2) NCT02794883
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery (Phase 1) NCT02812420
Ipilimumab for Head and Neck Cancer Patients (Phase 1) NCT02812524
Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (Phase 2) NCT02823574
Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas (Phase 1) NCT02829931
A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer (Not Applicable) NCT02833233
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (Phase 2) NCT02834013
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (Phase 1) NCT02846376
Yervoy Pregnancy Surveillance Study () NCT02854488
A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT02857569
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy (Phase 3) NCT02864251
Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients (Phase 2) NCT02866383
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers (Phase 4) NCT02869789
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (Phase 3) NCT02872116
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia (Phase 1) NCT02879695
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery (Phase 2) NCT02880020
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer (Phase 2) NCT02888743
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia (Phase 1) NCT02890329
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer (Phase 2) NCT02892734
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (Phase 3) NCT02899299
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors (Phase 1|Phase 2) NCT02904226
A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma (Phase 3) NCT02905266
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases (Phase 1|Phase 2) NCT02913417
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma (Phase 2) NCT02917772
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity (Phase 2) NCT02919683
IL2 Imaging in Metastatic Melanoma (Not Applicable) NCT02922283
A Study of RGX-104 in Patients With Advanced Solid Malignancies and Lymphoma (Phase 1) NCT02922764
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers (Phase 2) NCT02923934
A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (Phase 2) NCT02935634
Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab (Phase 1) NCT02935790
Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma () NCT02938728
Ipilimumab and Nivolumab in Leptomeningeal Metastases (Phase 2) NCT02939300
Real-Life Efficacy and Safety of Nivolumab in Patients With Advanced/Metastatic Renal Cell Carcinoma After Prior Therapy () NCT02940639
A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases (Phase 1|Phase 2) NCT02941744
A Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma (Phase 1) NCT02950766
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation (Phase 2) NCT02953457
A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naﾃｯve Metastatic Kidney Cancer (Phase 2) NCT02960906
Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy (Phase 2) NCT02968303
Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma (Phase 2) NCT02970981
Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (Phase 2) NCT02977052
Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (Phase 1) NCT02977156
A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab (Phase 2) NCT02978443
A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma (Phase 2) NCT02982486
A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (Phase 4) NCT02982954
A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors (Phase 1|Phase 2) NCT02983045
Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (Phase 2) NCT02985957
Real-Life Efficacy and Safety of Nivolumab Monotherapy or in Combination With Ipilimumab in Patients With Advanced (Unresectable or Metastatic) Melanoma and in Patients With Adjuvant Nivolumab Therapy () NCT02990611
Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (Phase 2) NCT02992912
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (Phase 2) NCT02996110
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (Phase 3) NCT02998528
An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) (Phase 2) NCT03001882
ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma (Phase 1|Phase 2) NCT03003637
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver (Phase 1) NCT03005002
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (Phase 1|Phase 2) NCT03009058
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas (Phase 1|Phase 2) NCT03013491
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (Phase 2) NCT03026062
Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity (Phase 2) NCT03026140
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer (Phase 1|Phase 2) NCT03026166
An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma (Phase 2) NCT03029780
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery (Phase 2) NCT03033576
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer (Phase 3) NCT03036098
Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer (Phase 1|Phase 2) NCT03043599
A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (Phase 3) NCT03048136
Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma (Phase 2) NCT03048474
Precise Local Injection of Anti-cancer Drugs Using Presage’s CIVO邃｢ Device in Soft Tissue Sarcoma (Phase 1) NCT03056599
Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature (Phase 2) NCT03061539
Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients (Phase 2) NCT03065179
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (Phase 3) NCT03068455
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Participants With Metastatic Uveal Melanoma (Phase 1) NCT03068624
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma (Phase 2) NCT03070392
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma (Phase 2) NCT03071406
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC (Phase 2) NCT03075423
BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer (Phase 2) NCT03083691
Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer (Phase 2) NCT03091491
Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma (Phase 2) NCT03097939
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab (Phase 1) NCT03098160
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer (Phase 2) NCT03101566
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer (Phase 2) NCT03104439
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors (Phase 1|Phase 2) NCT03110107
Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma (Phase 2) NCT03117309
A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy (Phase 2) NCT03122522
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies (Phase 1|Phase 2) NCT03126110
SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients (Phase 2) NCT03126461
An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (Phase 2) NCT03130959
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer (Early Phase 1) NCT03132467
SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma (Phase 1|Phase 2) NCT03138161
A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (Phase 3) NCT03138512
Immune Checkpoint Inhibitors and Pre-existing Autoimmune Diseases () NCT03140137
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (Phase 3) NCT03141177
A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (Phase 3) NCT03143153
Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer (Phase 1) NCT03144778
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer (Phase 2) NCT03146650
Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab (Phase 2) NCT03149159
A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma (Phase 2) NCT03153085
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer (Phase 2) NCT03158129
Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma (Phase 1|Phase 2) NCT03161756
Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer (Early Phase 1) NCT03162731
Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread () NCT03165409
A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan () NCT03165422
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) (Phase 1|Phase 2) NCT03168464
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment (Phase 2) NCT03171064
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer (Phase 2) NCT03172624
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (Phase 2) NCT03177239
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer (Phase 2) NCT03190265
Study of Nivolumab in Combination With Ipilimumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors (Phase 1|Phase 2) NCT03195478
Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer (Phase 1) NCT03203304
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) (Phase 2) NCT03203473
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors (Phase 1) NCT03203876
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer (Phase 2) NCT03204812
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (Phase 3) NCT03215706
Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) (Phase 2) NCT03219671
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma (Phase 2) NCT03219775
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma (Phase 2) NCT03220009
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer (Phase 2) NCT03222076
Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer (Phase 1) NCT03223155
Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma (Not Applicable) NCT03225365
Safety and Pharmacokinetics of REGN2810 (Anti-PD-1) in Japanese Patients With Advanced Malignancies (Phase 1) NCT03233139
Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma (Phase 1) NCT03233152
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (Phase 2) NCT03235245
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies (Phase 1|Phase 2) NCT03241173
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma (Phase 2) NCT03241186
Nivolumab Plus Ipilimumab in Thyroid Cancer (Phase 2) NCT03246958
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors (Phase 1|Phase 2) NCT03251924
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC (Phase 2) NCT03256136
Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. (Phase 2) NCT03262779
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation (Phase 1|Phase 2) NCT03271047
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma (Phase 2) NCT03274258
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma (Phase 1) NCT03283046
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) (Phase 2) NCT03285321
TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer (Phase 1|Phase 2) NCT03287674
TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma (Phase 1) NCT03293784
Adoptive Cell Therapy Across Cancer Diagnoses (Phase 1|Phase 2) NCT03296137
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma (Phase 1|Phase 2) NCT03297463
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma (Phase 2) NCT03297593
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (Phase 2) NCT03297606
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598) (Phase 3) NCT03302234
Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL (Phase 1|Phase 2) NCT03305445
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery (Phase 2) NCT03307616
Expanded Access for Pembrolizumab (MK-3475) () NCT03311542
Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma (Phase 2) NCT03313323
Study of Adverse Renal Effects of Immune Checkpoints Inhibitors () NCT03316417
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery (Phase 1|Phase 2) NCT03326258
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors (Phase 2) NCT03333616
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (Phase 1) NCT03335540
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (Phase 2) NCT03340129
Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients (Phase 2) NCT03342417
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208) (Phase 1|Phase 2) NCT03347123
TNF in Melanoma Patients Treated With Immunotherapy (Not Applicable) NCT03348891
Interest of iRECIST Evaluation for DCR for Evaluation of Patients With Deficient MMR and /or MSI Metastatic Colorectal Cancer Treated With Nivolumab and Ipilimumab (Phase 2) NCT03350126
Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly Patients With Advanced Non-small Cell Lung Cancer (Phase 3) NCT03351361
ANRS CO24 OncoVIHAC (Onco VIH Anti Checkpoint) () NCT03354936
Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) (Phase 1|Phase 2) NCT03354962
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas (Phase 2) NCT03355976
Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma (Phase 2) NCT03367715
An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread (Phase 1|Phase 2) NCT03369223
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer (Phase 1) NCT03373188
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer (Phase 2) NCT03373760
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer (Phase 1|Phase 2) NCT03377023
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread (Phase 1|Phase 2) NCT03377361
Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions () NCT03387540
Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (Phase 1) NCT03387761
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers (Phase 1) NCT03388632
Phase III Trial of (LCT) After Nivolumab and Ipilimumab (Phase 3) NCT03391869
Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma (Phase 2) NCT03396952
Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Phase 1|Phase 2) NCT03404960
Immunotherapy in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab (Phase 2) NCT03406247
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac – Patients With Small Cell Lung Cancer (SCLC) (Phase 2) NCT03406715
A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV) (Phase 1) NCT03407105
CAVATAKﾂｮ and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) (Phase 1) NCT03408587
Biomarkers of Immune-Related Toxicity () NCT03409016
Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer (Phase 2) NCT03409198
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer (Phase 3) NCT03409614
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma (Phase 2) NCT03409848
A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer (Phase 2) NCT03416244
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors (Phase 2) NCT03420521
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma (Phase 1) NCT03422094
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer (Phase 1) NCT03425292
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC (Phase 2) NCT03425331
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma (Phase 1) NCT03425461
A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer (Phase 2) NCT03430063
Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Bevacizumab-naﾃｯve, Recurrent Glioblastoma (Phase 2) NCT03430791
Combination of Chemoradiation With Immunotherapy in Inoperable ﾅ都ophageal Cancer (Phase 2) NCT03437200
Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy () NCT03438279
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC (Phase 2) NCT03442569
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence (Phase 2) NCT03443856
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed (Phase 1) NCT03444753
A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) (Phase 3) NCT03445533
Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom () NCT03448497
Long Term Quality of Life in Melanoma Patients in Netherlands () NCT03450876
Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers (Phase 1) NCT03452332
Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition () NCT03453892
Improved Therapy Response Assessment in Metastatic Brain Tumors () NCT03458455
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread (Phase 1|Phase 2) NCT03459222
An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas () NCT03460782
Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) (Phase 2) NCT03461952
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma (Early Phase 1) NCT03463408
Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer (Phase 2) NCT03468985
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (Phase 3) NCT03469960
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver (Phase 2) NCT03472586
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer (Phase 1) NCT03477864
Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction () NCT03492242
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (Phase 1) NCT03493932
Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer (Phase 1) NCT03507699
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis (Phase 1) NCT03508570
Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients (Phase 1) NCT03509584
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) (Phase 2) NCT03510871
REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer (Phase 3) NCT03515629
A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy (Phase 2) NCT03520491
Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma (Phase 2) NCT03521830
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Phase 1|Phase 2) NCT03522584
ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors (Phase 1|Phase 2) NCT03525795
A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes (Early Phase 1) NCT03526185
Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC (Phase 1) NCT03527251
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma (Phase 2) NCT03528408
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer (Phase 1) NCT03532217
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma (Phase 1) NCT03538314
Peri-Operative Ipilimumab+Nivolumab and Cryoablation Versus Standard Care in Women With Triple-negative Breast Cancer (Phase 2) NCT03546686
Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) (Phase 2) NCT03548428
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma (Phase 2) NCT03552380
Melanoma Metastasized to the Brain and Steroids (Phase 2) NCT03563729
A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma (Phase 1) NCT03565406
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (Phase 2) NCT03570619
Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC (Phase 2) NCT03573947
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer (Phase 1|Phase 2) NCT03575793
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer (Phase 1|Phase 2) NCT03581487
Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (Phase 2) NCT03591731
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma (Phase 1) NCT03597282
PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma (Phase 2) NCT03598816
Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome (Phase 1) NCT03600155
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer (Phase 2) NCT03601455
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma (Phase 1|Phase 2) NCT03604978
Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery (Phase 2|Phase 3) NCT03604991
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner (Phase 1|Phase 2) NCT03618134
CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease (Phase 2) NCT03618641
A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck (Phase 2) NCT03620123
Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients (Not Applicable) NCT03627026
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab (Phase 2) NCT03638141
A Study of a Personalized Neoantigen Cancer Vaccine (Phase 1|Phase 2) NCT03639714
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma (Phase 2) NCT03646617
Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer (Phase 2) NCT03647969
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients (Phase 2) NCT03650894
Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer (Phase 2) NCT03651271
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) (Phase 1|Phase 2) NCT03663166
A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread () NCT03663946
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (Phase 2) NCT03668119
A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy (Phase 2) NCT03670056
Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma (Phase 1|Phase 2) NCT03682276
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer (Phase 1) NCT03690986
INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma (Not Applicable) NCT03692338
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors (Phase 2) NCT03693014
Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors (Phase 2) NCT03693846
A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen. () NCT03695835
Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy (Phase 3) NCT03700905
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma (Phase 1) NCT03707457
Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab (Phase 1) NCT03707808
A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma (Phase 2) NCT03711188
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy (Phase 2) NCT03719131
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression (Phase 2) NCT03724968
RACIN in Patients With Advanced TIL-negative Solid Tumors (Phase 1) NCT03728179
Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma (Phase 2) NCT03728465
A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US () NCT03732560
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers (Phase 1|Phase 2) NCT03749460
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome (Phase 2) NCT03767439
VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma (Phase 1) NCT03769155
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer (Phase 1|Phase 2) NCT03776487
Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer – a Combination Immunotherapy Phase Ib Study. (Phase 1) NCT03784040
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer (Phase 2) NCT03789110
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (Phase 3) NCT03793166
Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer (Phase 1) NCT03798639
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma (Phase 2) NCT03799445
CAcTUS – Circulating Tumour DNA Guided Switch (Phase 2) NCT03808441
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (Phase 1) NCT03816332
Anetumab Ravtansine With Nivolumab, Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Mesothelin Positive Advanced Pancreatic Cancer (Phase 1) NCT03816358
Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease (Phase 2) NCT03818685
An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) (Phase 2) NCT03823625
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer (Phase 1) NCT03829111
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer (Phase 2) NCT03832621
A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study (Phase 1|Phase 2) NCT03844256
Radiation and Combination Immunotherapy for Melanoma (Phase 2) NCT03850691
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) (Phase 2) NCT03865082
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (Phase 2) NCT03866382
Autoantibodies in Treatment With Immune Checkpoint Inhibitors (AUTENTIC) () NCT03868046
An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer (Phase 3) NCT03873402
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain (Phase 2) NCT03873818
A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (Phase 1) NCT03878524
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer (Phase 2|Phase 3) NCT03879122
Optune Device – TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis (Phase 2) NCT03903640
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT (Phase 1) NCT03912064
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer (Phase 2) NCT03914300
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma (Phase 1|Phase 2) NCT03918252
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma (Phase 1) NCT03922880
Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma (Phase 1) NCT03929029
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (Phase 3) NCT03937219
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors (Phase 2) NCT03945773
Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis (Phase 1|Phase 2) NCT03949153
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens (Phase 1|Phase 2) NCT03953235
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers (Phase 1) NCT03956680
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma (Phase 1|Phase 2) NCT03958383
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma (Phase 2) NCT03959293
Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial (Phase 3) NCT03977571
A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment (Phase 1) NCT03978611
Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy (Phase 1) NCT03982121
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (Phase 2) NCT03989362
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors (Phase 2) NCT03993379
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma (Phase 2) NCT03999749
IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With Recurrent or Refractory Glioblastoma (Phase 1) NCT04003649
Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma (Phase 2) NCT04006262
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma (Phase 2) NCT04007588
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Patients With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (Phase 3) NCT04008030
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer (Phase 1) NCT04013542
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab (Phase 2) NCT04013854
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers (Phase 1|Phase 2) NCT04021043
Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma (Phase 1|Phase 2) NCT04021420
A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 NSCLC That is Unable or Not Planned to be Removed by Surgery (Phase 3) NCT04026412
ImmunoPET With an Anti-CD8 Imaging Agent (Phase 1|Phase 2) NCT04029181
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (Phase 2) NCT04034927
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (Phase 3) NCT04039607
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors (Phase 2) NCT04042753
Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (Phase 1|Phase 2) NCT04043195
A Prospective Observational Study of Renal Cell Cancer Patients Treated With Nivolumab Plus Ipilimumab in the Real World Setting in Japan () NCT04043975
CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (Phase 1|Phase 2) NCT04060407
Perioperative Chemotherapy vs Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG (Phase 2) NCT04062656
Study of ARRY-614 Plus Either Nivolumab or Ipilimumab (Phase 1|Phase 2) NCT04074967
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors (Phase 2) NCT04079712
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer (Phase 2) NCT04080804
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma (Phase 2) NCT04088500
SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (Phase 2) NCT04090710
A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma (Phase 2) NCT04090775
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma (Phase 2) NCT04091750
Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintalolimid, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (Phase 2) NCT04093323
Microbiome Immunotherapy Toxicity and Response Evaluation () NCT04107168
Phase IB/II Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer (Phase 1|Phase 2) NCT04109729
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer (Phase 1) NCT04117087
Ipilimumab +Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma (Phase 2) NCT04118166
Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer (Phase 2) NCT04124601
Nivolumab/Ipilimumab in Second Line CUP-syndrome (Phase 2) NCT04131621
A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2-Breast Cancer That Has Spread (Phase 1) NCT04132817
Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (Phase 1|Phase 2) NCT04133948
Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. (Phase 2) NCT04134182
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics () NCT04136470
PhIb Study Evaluating Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC (Phase 1) NCT04141644
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) for People With Recurrent Glioblastoma With Elevated Mutational Burden (Phase 2) NCT04145115
AImmune – Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient’s Response to Immunotherapies. () NCT04145232
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response () NCT04146064
CaboCHECK – Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study () NCT04147143

がん免疫療法免疫チェックポイント阻害薬(ICI) Ipilimumabの効果　～抗CTLA-4抗体～

2018年に本庶佑博士とともにノーベル医学生理学賞を受賞したジェームス・アリソン博士が、最初の臨床試験のことを語るインタビュー動画。

2015 Lasker DeBakey Clinical Medical Research Award 2015/09/07 Albert and Mary Lasker Foundation

Talks@12: Immunotherapy: An Answer to Cancer? 2017/11/07 Harvard Medical School

1 抗CTLA-4抗体(免疫チェックポイント阻害薬)の最初の臨床試験で効果があった患者さんのストーリー
- 1.1 Sharon Belvinさんのストーリー
- 1.2 Tom Telfordさんのストーリー
2 ipilimumabをFDAが承認
3 臨床試験
4 臨床試験の結果を報告した論文
5 抗CTLA-4抗体の効果を調べた初期の論文

抗CTLA-4抗体(免疫チェックポイント阻害薬)の最初の臨床試験で効果があった患者さんのストーリー

Sharon Belvinさんのストーリー

上の動画でも登場したSharon Belvinさんのストーリー。

She’s the Answer to Cancer…and So Are You 2016/05/06 Cancer Research Institute

Milestones in Medicine: How Immunotherapy Began in Cancer Care A look back at how immunotherapy began in oncology. (ARLENE WEINTRAUB SEPTEMBER 25, 2019 curetoday.com) Sharon Belvin was 23 and running out of options to treat her stage 4 melanoma in 2005 when her oncologist at Memorial Sloan Kettering Cancer Center in New York City offered to enter her in a clinical trial of a drug designed to empower her immune system to fight the cancer. By that point, she had progressed after several rounds of chemotherapy, plus radiosurgery to remove tumors that had spread to her brain. The drug blocked CTLA-4, a protein “checkpoint” that prevents the immune system from recognizing and attacking cancer. After just four treatments, 60% of Belvin’s tumors were gone. Within months, they had all disappeared, and she has been cancer-free ever since. In 2011, that drug, Yervoy (ipilimumab), became the first checkpoint inhibitor to be approved by the Food and Drug Administration (FDA).
For this Nobel winner, fighting cancer began with his family （Oct 1, 2018 6:25 PM EST PBS) アリソン博士が2018年ノーベル医学生理学賞を受賞した直後のPBS NEWSのインタビュー動画（７：２６）トランスクリプト付き
Melanoma survivor’s unlikely recovery leads to lifestyle changes (Oct 1, 2017 sungazette.com) The treatment involved 90-minute infusions and injections in Belvin’s leg. … But the radiologist had never seen anything like it. He had to verify he’d grabbed the right labs. My tumors had shrunk by 60 percent in that first round.
A Scientist’s Dream Fulfilled: Harnessing The Immune System To Fight Cancer (June 9, 2016 3:41 PM ET Heard on All Things Considered NPR) Sharon Belvin’s nightmare with cancer began in 2004, when she was just 22.
Six Miracle Cancer Survivors (Robert Langreth Mar 2, 2009, 04:50pm forbes.com) An experimental drug helped Sharon Belvin, who was diagnosed with melanoma in her lung when she was 22 and spent two years in standard treatment. The drug is called ipilimumab, and it aims to trigger the immune system against cancer. Within four months, her lung tumors started to shrivel. By late 2006, they were gone. Today Belvin, now 27, is off all treatment.

Tom Telfordさんのストーリー

How the Promise of Immunotherapy Is Transforming Oncology (Tom Telfordさんのストーリー　WSJ ） He had surgery at Memorial Sloan Kettering Cancer Center, followed by months of chemotherapy. But the disease spread to his liver and kidneys. The diagnosis: Stage 4 melanoma, a skin cancer typically fatal within a year. “Death is not an option,” he told his doctor. Nine years later, against all odds, Mr. Telford is still alive. What saved him was an experimental immunotherapy drug—a medication that unleashes the body’s own immune system to attack cancer.

ipilimumabをFDAが承認

On 25 March, the FDA cleared ipilimumab, produced by Bristol-Myers Squibb, based in New York, to treat advanced melanoma, a particularly lethal form of skin cancer. Although the drug typically lengthens a patient’s life by only 4 months or so, in clinical trials a fraction of patients lived much longer.

Although ipilimumab can add years of life, only 20–30% of patients show any benefit at all (F. S. Hodi et al. N. Engl. J. Med. 363, 711–723; 2010).

（引用元：Melanoma drug wins US approval. Nature volume 471, page 561 (2011) 28 March 2011）

臨床試験

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma (Phase 3)(NCT00094653) Study Type : Interventional (Clinical Trial) Actual Enrollment : 1783 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment Official Title: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma Study Start Date : September 2004 Actual Primary Completion Date : August 2009 Actual Study Completion Date : October 2009
IPILIMUMABの臨床試験（NIH ClinicalTrials.govデータベースの検索結果）

臨床試験の結果を報告した論文

The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun. 2008; 8: 1. Published online 2008 Jan 17. PMCID: PMC2935787 Results from preclinical and early clinical trials support currents phase II/III testing of ipilimumab as first- and second-line therapy for metastatic melanoma.
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009 Feb 12;113(7):1581-8. doi: 10.1182/blood-2008-07-168468. Epub 2008 Oct 30. Twenty-nine patients with malignancies that were recurrent or progressive after allo-HCT, received ipilimumab as a single infusion at dose cohorts between 0.1 and 3.0 mg/kg. … Three patients with lymphoid malignancy developed objective disease responses following ipilimumab: complete remission (CR) in 2 patients with Hodgkin disease and partial remission (PR) in a patient with refractory mantle cell lymphoma. At the 3.0 mg/kg dose, active serum concentrations of ipilimumab were maintained for more than 30 days after a single infusion. Ipilimumab, as administered in this clinical trial, does not induce or exacerbate clinical GVHD, but may cause organ-specific IAE and regression of malignancy.
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. August 19, 2010 N Engl J Med 2010; 363:711-723 DOI: 10.1056/NEJMoa1003466 METHODS A total of 676 HLA-A*0201–positive patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease, were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136). RESULTS The median overall survival was 10.0 months among patients receiving ipilimumab plus gp100, as compared with 6.4 months among patients receiving gp100 alone (hazard ratio for death, 0.68; P<0.001). CONCLUSIONS Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Investigational New Drugs June 2011, Volume 29, Issue 3, pp 489–498 (Free abstract)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015 Jun 10;33(17):1889-94. doi: 10.1200/JCO.2014.56.2736. Epub 2015 Feb 9.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. October 5, 2017 N Engl J Med 2017; 377:1345-1356 DOI: 10.1056/NEJMoa1709684 ２つのICIを併用した効果をみたもの

抗CTLA-4抗体の効果を調べた初期の論文

Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996 Mar 22;271(5256):1734-6. (PDF) We reasoned that CTLA-4 blockade would remove inhibitory signals in the costimulatory pathway, resulting in enhanced rejection of the tumor cells. We injected groups of BALB/c mice …

脳震盪とは　concussion / a mild traumatic brain injury (mTBI)

1 脳震盪とは
2 スポーツ脳震盪のアセスメント

脳震盪とは

“Concussion Management” by Michael O’Brien for OPENPediatrics 2018/08/10 OPENPediatrics

スポーツ脳震盪 (MSDメルクマニュアルプロフェッショナル版)

Concussions: Heading for Change – an NET Sports Feature 2014/11/12 NETNebraska

スポーツ脳震盪のアセスメント

SCAT5 – Sport Concussion Assessment Toolの実際。
SCAT5 – Sport Concussion Assessment Tool 2018/07/18 Aspetar

ディープウェブとダークウェブ

通常のインターネットブラウザでアクセスしているのは、インターネット全体のほんの氷山の一角なのだそうです。水面下にある部分はディープウェブと言われます。ディープウェブの一部に、ダークウェブがあります。

Why You Should Never Visit The Dark Web 2019/01/31 The Infographics Show

マクロライド系抗生物質の作用機序

Macrolides: Mechanisms of Action and Resistance 2011/03/30 Mechanisms in Medicine

エクソソームの検出、定量キットの使い方の実際【動画による説明】

How to use ExoTEST Kit (kit for exosome capture and quantification) 2015/07/25 HansaBioMed Life Sciences Ltd

シェーグレン症候群（Sjögren症候群）とは

1 シェーグレン症候群とは
2 シェーグレン症候群の症状
3 シェーグレン症候群の病態・診断・治療、診療ガイドライン
- 3.1 シェーグレン症候群の診断基準
- 3.2 抗SS-A抗体と抗SS-B抗体
4 シェーグレン症候群を罹患した著名人

シェーグレン症候群とは

シェーグレン症候群は1933年にスウェーデンの眼科医ヘンリック・シェーグレンの発表した論文にちなんでその名前がつけられた疾患です。日本では1977年の厚生労働省研究班の研究によって医師の間に広く認識されるようになりました。本疾患は主として中年女性に好発する涙腺と唾液腺を標的とする臓器特異的自己免疫疾患ですが、全身性の臓器病変を伴う全身性の自己免疫疾患でもあります。シェーグレン症候群は膠原病（関節リウマチ、全身性エリテマトーデス、強皮症、皮膚筋炎、混合性結合組織病）に合併する二次性シェーグレン症候群と、これらの合併のない原発性シェーグレン症候群に分類されます。（指定難病53　難病情報センター）

シェーグレン症候群の症状

一部の患者では、口または眼の乾燥だけがみられます。…　多数の臓器が侵される場合もあります。シェーグレン症候群では、鼻、咽頭、消化管、喉頭、気管、気管支、外陰部、腟の表面を覆っている粘膜が乾燥することがあります。（MSDマニュアル家庭版）

シェーグレン症候群（SS）（MSDマニュアル　プロフェッショナル版）

Sjögren’s syndrome 2014/02/25 Dr. Andras Fazakas

シェーグレン症候群の病態・診断・治療、診療ガイドライン

シェーグレン症候群診療ガイドライン2017年版（１３０ページPDF)　厚生労働科学研究費補助金　難治性疾患等政策研究事業　自己免疫疾患に関する調査研究班
シェーグレン症候群：病態・診断・治療　(第 114 回日本内科学会講演会超世代の内科学―GeneralityとSpecialtyの先へ―　本講演は，平成29年4月16日（日）東京都・東京国際フォーラムにて行われた．)
成人のシェーグレン症候群の特徴と治療（総説　臨床リウマチ，29： 219～227，2017）

シェーグレン症候群の診断基準

シェーグレン症候群（SjS）改訂診断基準（厚生労働省研究班、1999 年）
１．生検病理組織検査で次のいずれかの陽性所見を認めること
A）口唇腺組織でリンパ球浸潤が 1/4m ㎡当たり 1focus 以上
B）涙腺組織でリンパ球浸潤が 1/4m ㎡当たり 1focus 以上
２．口腔検査で次のいずれかの陽性所見を認めること
A）唾液腺造影で stage I（直径 1mm 以下の小点状陰影）以上の異常所見
B）唾液分泌量低下（ガムテスト 10 分間で 10mL 以下，またはサクソンテスト 2 分間 2g 以下）があり、かつ唾液腺シンチグラフィーにて機能低下の所見
３．眼科検査で次のいずれかの陽性所見を認めること
A）Schirmer 試験で 5mm/5min 以下で、かつローズベンガルテスト（van Bijsterveld スコア）で陽性
B）Schirmer 試験で 5mm/5min 以下で、かつ蛍光色素（フルオレセイン）試験で陽性
４．血清検査で次のいずれかの陽性所見を認めること
A）抗 SS-A 抗体陽性
B）抗 SS-B 抗体陽性

診断以上１、２、３、４のいずれか２項目が陽性であればシェーグレン症候群と診断する。(転載元）

抗SS-A抗体と抗SS-B抗体

これらの自己抗体の名前の由来に関しては、下のレビューでわかりやすく解説されています。

Anti-Ro/SSA and anti-La/SSB antibodies were originally described in 1961 as two precipitating antibodies reacting with antigens contained in extracts from salivary and lacrimal glands of patients with SS, termed SjD, and SjT, respectively [9]. SjD antigen was reported to be insensitive to trypsin or heat, while SjT antigen could be destroyed by the same treatment. In 1969, Clark et al. described the presence of antibodies in the sera of patients with SLE that reacted with ribonucleoprotein (RNP) antigens present in extracts of rabbit and human spleen [10]. The authors named the antibody “anti-Ro antibody” after the original patient in whom the antibodies were identified. The same group also found antibodies to another soluble cytoplasmic RNA protein antigen, “La” [11]. At about the same time, Alspaugh and Tan noted the existence of autoantibodies in the sera of many SS patients, which react with antigens termed “SSA” and “SSB,” [12]. SSB antigen was described also as “Ha”, an antigen targeted by sera from patients with SLE and SS [13]. Later, Ro and La were demonstrated to be antigenically identical to SSA and SSB [14]. (Clinical and Developmental Immunology Volume 2012, Article ID 606195, 12 pages http://dx.doi.org/10.1155/2012/606195 Review Article Clinical and Pathological Roles of Ro/SSA Autoantibody System Ryusuke Yoshimi, Atsuhisa Ueda, Keiko Ozato, and Yoshiaki Ishigatsubo　著作権：CC BY 3.0)

抗SS-A/Ro抗体と抗SS-B/La抗体は共に非ヒストン核蛋白抗体のひとつであり，シェーグレン症候群と密接に関連している。しかし，抗SS-A抗体は多くの膠原病で陽性を示す。（抗SS-A/Ro抗体　SRL総合案内）

異常値を示す主な疾患・状態・異常高値：シェーグレン症候群の50～70％　全身性エリテマトーデス（SLE）の40～60％　重複症候群の40～60％　強皮症の10～30％　多発性筋炎／皮膚筋炎の10～20％　関節リウマチの20～30％（抗SS-A／Ro抗体　FALCO臨床検査案内サイト）

抗SS-A抗体はシェーグレン症候群の70～90%と最も高頻度に検出されますが、疾患特異性は高くなく、全身性エリテマトーデス（SLE）や強皮症、混合性結合組織病（MCTD）、関節リウマチなど他の膠原病でも広く陽性となります。RNAと蛋白の複合体に対する自己抗体で、対応抗原は細胞質に多く存在するため抗核抗体陰性でも抗SS-A抗体が検出されることがあります。　一方、抗SS-B抗体はシェーグレン症候群の30～40%に検出され、特異性が高く、抗SS-B抗体陽性の場合、抗SS-A抗体も同時に陽性となります。RNAポリメラーゼIIIの転写産物と複合体を形成する蛋白に対する自己抗体で、対応抗原は核内に存在するため抗核抗体ではSpeckled型陽性を示します。（CRC)

抗 SS-A 抗体陽性女性の妊娠に関する診療の手引き　（2013 年 3 月　平成 22 年度～平成 24 年度厚生労働科学研究費補助金成育疾患克服等次世代育成基盤研究事業）抗 SS-A 抗体は全身性エリテマトーデス(SLE)やシェーグレン症候群(SS)で高率に認められる自己抗体であるが、無症候性の女性が保有している場合もある。抗 SS-A 抗体陽性女性から出生する児における NLE の発症率は約 10％、そのうち CHBは約1％(すなわち、全国での年間発症数は約100 例)と推定されている[2]。
シェーグレン症候群患者が妊娠する場合に注意することはありますでしょうか？（FAQ　指定難病５３　難病情報センター)　抗SS-A抗体という抗体をお持ちですと、新生児に房室ブロックという不整脈が出ることがまれにあります。また、新生児ループスといって、生まれた赤ちゃんにお母さんの自己抗体が移行し、真っ赤になって（赤ちゃんはもともと赤いから赤ちゃんなのですがさらに真っ赤に）生まれる事がまれにあります。
Franceschini F, Cavazzana. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity. 2005 Feb;38(1):55-63. (PubMed) The Ro/La system is considered as an heterogeneous antigenic complex, constituted by three different proteins (52 kDa Ro, 60 kDa Ro and La) and four small RNAs particles.
Ben-Chetrit E. Target antigens of the SSA/Ro and SSB/La system. Am J Reprod Immunol. 1992 Oct-Dec;28(3-4):256-8. (PubMed) The SSA/Ro and SSB/La antigens are polypeptides which serve as autoantigens in systemic lupus erythematosus and Sjogren’s syndrome. The SSA/Ro contains two major isoforms of 60 kD and 52 kD. The former is the main native antigen while the latter is a major autoantigen in its denatured form. The SSB/La is a single phosphorylated protein of 48 kD.
Elaine L. AlexanderThomas T. Provost. Ro (SSA) and La (SSB) antibodies. Springer Seminars in Immunopathology September 1981, Volume 4, Issue 3, pp 253–273

残念ながら根本的にシェーグレン症候群を治癒させることはできません。乾燥症状に対しては症状を軽くすること、他の臓器障害に対してはそれらを抑えることを目的とした治療を行います。（シェーグレン症候群（Sjögren’s syndrome: SS）しぇーぐれんしょうこうぐん　KOMPAS　慶応義塾大学　医療・健康情報サイト）

シェーグレン症候群 Sjögren’s syndrome，SjS　（順天堂大学医学部　膠原病・リウマチ内科）
シェーグレン症候群の臨床～シェーグレン症候群は最も身近な膠原病～　2004年

シェーグレン症候群を罹患した著名人

和田アキ子が告白した難病「シェーングレン症候群」の怖さ (2011.03.03 16:00 女性セブン / livedoor NEWS) 和田アキ子（60）が2月26日、自身のラジオ番組で、シェーグレン症候群にかかっている可能性があることを告白した。翌27日放送の『アッコにおまかせ！』（TBS系）では、「大丈夫。寝込むほどの病気じゃないから」と語っていたが、実はこの病気、東京都などの自治体が指定する難病のひとつだ。
菊池桃子離婚前から難病「シェーグレン症候群」を患っていた (2012.3.2 10:58週刊朝日 AERAdot.) 1月28日、プロゴルファーの西川哲（43）と17年続いた結婚生活にピリオドを打ったことを発表した菊池桃子（43）。中学3年と小学4年の子どもを抱え、今後は女優業に本格復帰すると思われていた……。そんな矢先に衝撃的なニュースが飛び込んできた。離婚をする以前から菊池が難病に苦しんでいたというのだ。本誌の取材によると、菊池が患った病は「シェーグレン症候群」。

臨床医のための臨床研究テーマの見つけ方

1 臨床研究を行う理由
2 臨床研究テーマの見つけ方
3 書籍
4 参考

臨床研究を行う理由

T医師が漠然と感じているような疑問は、臨床に携わっていると日常的に沸き起こってくるはずです。…

「臨床研究」とは、このような漠然とした疑問を、検証可能な「リサーチクエスチョン」として構造化させ、科学的な手法を用いて解決していく過程です。そして疑問を解決していく中で、また新たなリサーチクエスチョンが生まれて来る。そのような連鎖が、臨床医学を前へと進める推進力であり、臨床研究のだいご味です。（臨床研究者育成プログラムのご紹介　東京大学医学部）

病気を深く知ろうとする行為そのものが研究であると考えれば、よい臨床医になるためには研究という作業が必ず伴うのではなかろうか。（京都大学大学院医学研究科・医学部　皮膚科学　教授エッセイ）

臨床研究テーマの見つけ方

臨床研究の大きな流れとしては、まず「後向き研究」からスタートして糸口をつかみ、「前向き研究」の「観察研究」で方向性を定め、さらに「介入研究（臨床試験）」で確認する、というのが王道ですね。…

こうした疑問点をガイドラインなどで調べても、エビデンスがはっきりしない場合がしばしばあります。こういう時こそ問題解決の一つのチャンスなので、さあ後向き研究をやろう、となるわけです。…

後向き研究をやってみると、何かしら解決すべき問題が出てきて、これを前向きに調べることになります。そこまでやると、自分のテーマとしてこれを突き詰めたくなる。（インタビュー第6回：神山圭介教授「治験」と「臨床研究」の違い　慶応義塾大学病院臨床研究推進センター）＊太字強調は当サイト

書籍

実践対談編臨床研究立ち上げから英語論文発表まで最速最短で行うための極意 (すべての臨床医そして指導医にも捧ぐ超現場型の臨床研究体験書) 2018/4/18 原正彦
臨床研究立ち上げから英語論文発表まで最速最短で行うための極意 (すべての臨床医に捧ぐ超現場重視型の臨床研究指南書) 2017/12/4 原正彦

『臨床研究英語論文最速最短』は臨床医に研究を勧めて、実際にアイデアの出し方から論文アクセプトに至るまでの道のりをガイドしてくれる本なのですが、基礎研究しか知らない自分が読んでも非常に面白く、大変役立つ内容でした。自分の研究の一番のブレーキになる上司とのかかわり方であるとか、論文原稿を教授が何か月も放置して読んでくれないときにどうすべきかなど、研究者がしばしば遭遇する困難への対処方法、実践的なアドバイスが満載です。

参考

臨床研究：実戦的基礎知識 国立国際医療研究センター「初期臨床で身につけたい臨床研究のエッセンス」Vol.2 第４章より抜粋・改変
Douglas A. Mata. Once You’ve Found the Question: How to Take the Next Steps in Research Nov 08, 2017 (NEJM Resident 360)
Sadaf Aslam and Patricia Emmanuel. Formulating a researchable question: A critical step for facilitating good clinical research. Indian J Sex Transm Dis AIDS. 2010 Jan-Jun; 31(1): 47–50. PMC3140151 step-by-step guidance on the formulation of a research question
David A. Katzka. How to Balance Clinical Work and Research in the Current Era of Academic Medicine. Gastroenterology. November 2017; Volume 153, Issue 5, Pages 1177–1180.

皮膚は怪我の後、どうやって治癒していくのか？メカニズムの解説

怪我をして皮膚を切ったりしたときに、人間の体はどのようにして傷を修復するのでしょうか？下の動画が非常にわかりやすく説明してくれます。

創傷が治癒する過程
ケガはどのように治るのか？－サルタック・シンハ 2014/11/11 TED-Ed

Stages of Wound Healing Process　2014/09/28　usmlesteps123

傷の修復過程で線維芽細胞（Fibroblasts)が傷のところに集まってきますが、その過程を模倣した実験観察の動画（下）。

Wound Repair and Fibroblast Migration 2016/09/19 Zar

心室中隔欠損症(Ventricular Septal Defect, VSD)の手術

Ventricular Septal Defect (VSD) Surgical Repair – Pediatric Heart Surgery 2008/08/20 Nicklaus Children’s Hospital

2019年度ノーベル化学賞はリチウムイオン電池の発明者　吉野彰、ジョン・グッドイナフ、スタンリー・ウィッティンガムの3氏に

1 2019年度ノーベル化学賞受賞者の発表
2 吉野彰氏の記者会見
3 リチウムイオン電池の誕生

2019年度ノーベル化学賞受賞者の発表

吉野彰氏の記者会見

ノーベル化学賞の旭化成・吉野彰氏「リチウムイオン電池が受賞してうれしい」（2019年10月9日 THE PAGE ザ・ページ）

吉野彰氏の略歴：
1966年 – 大阪府立北野高等学校卒業
1970年 – 京都大学工学部石油化学科卒業
1972年 – 京都大学大学院工学研究科石油化学専攻修士課程修了
1972年 – 旭化成工業株式会社（現旭化成株式会社）入社
（参照：ウィキペディア）

リチウムイオン電池の誕生

2018 Japan Prize Commemorative Lecture: Dr. Akira Yoshino 　2018/04/23 　JapanPrize

16S rRNAのシーケンシングによる細菌の種類の同定

Detection and identification of bacteria in clinical samples by 16S rRNA gene sequencing:comparison of two different approaches in clinical practice
https://www.microbiologyresearch.org/docserver/fulltext/jmm/61/4/483_jmm030387.pdf?expires=1570540556&id=id&accname=guest&checksum=5420BE74E3BA950EA45B92F013CBE211

Efficient Nucleic Acid Extraction and 16S rRNA Gene Sequencing for Bacterial Community Characterization
https://www.jove.com/video/53939/efficient-nucleic-acid-extraction-16s-rrna-gene-sequencing-for
<a title="Efficient Nucleic Acid Extraction and 16S rRNA Gene Sequencing for Bacterial Community Characterization" href="https://www.jove.com/video/53939/efficient-nucleic-acid-extraction-16s-rrna-gene-sequencing-for">Efficient Nucleic Acid Extraction and 16S rRNA Gene Sequencing for Bacterial Community Characterization</a> </p> <p> </p> <p>

Using a 16S rRNA Sequence to Identify a Bacterial Isolate (2017/10/03　Oxford Academic (Oxford University Press))

What Is 16s rRNA sequencing？ (2018/08/01 CD Genomics)
https://www.youtube.com/watch?v=3UHiveJ1jzM

2019年度ノーベル物理学賞受賞者はJames Peebles, Michel Mayor , Didier Queloz の3氏に

1 2019年度ノーベル物理学賞の授与
2 2019年度ノーベル物理学賞発表の様子
3 参考

2019年度ノーベル物理学賞の授与

8 October 2019

The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Physics 2019

“for contributions to our understanding of the evolution of the universe and Earth’s place in the cosmos” with one half

to James Peebles Princeton University, USA

“for theoretical discoveries in physical cosmology” and the other half jointly

to Michel Mayor University of Geneva, Switzerland

and Didier Queloz University of Geneva, Switzerland University of Cambridge, UK

“for the discovery of an exoplanet orbiting a solar-type star” (nobelprize.org)

2019年度ノーベル物理学賞発表の様子

Announcement of the Nobel Prize in Physics 2019

参考

New perspectives on our place in the universe (Nobelprize.org)
Scientific Background on the Nobel Prize in Physics 2019 PHYSICAL COSMOLOGY AND AN EXOPLANET ORBITING A SOLAR-TYPE STAR (Nobelprize.org)

低酸素、腎臓、hypoxia-inducible factor (HIF) 、エリスロポエチン（Epo）について

2019年度ノーベル医学生理学賞は、低酸素刺激に対して生体がどのように反応するかに関する研究を行ったウィリアム・ケリン、ピーター・ラトクリフ、グレッグ・セメンザの3氏に贈られました。

1 hypoxia-inducible factor (HIF) の発見
2 エリスロポエチン（Epo）
3 腎臓と低酸素
4 HIF刺激薬

hypoxia-inducible factor (HIF) の発見

HIF-１は，肝がん細胞株 Hep３B において「低酸素依存的にエリスロポエチン（EPO）を誘導する因子」として１９９２年に Semenza らによって発見された．

Semenza, G.L. & Wang, G.L.（１９９２）Mol. Cell. Biol., １２, ５４４７―５４５４.

（引用元：生化学第８５巻第３号，pp.１８７―１９５，２０１３）

エリスロポエチン（Epo）

エリスロポエチン（Epo）は赤血球産生を制御する造血ホルモンであり、組織の低酸素に応答して産生され、骨髄などの造血細胞に働いて赤血球産生を刺激します（図2）。高地トレーニングをしている運動選手の血液では赤血球数、および、酸素運搬に関わるヘモグロビン量が増加しますが、これも低酸素環境におけるEpo産生の亢進によるものです。また、ヒトの大人ではEpoは主に腎臓において産生されます。(引用元：エリスロポエチン遺伝子の発現制御　dmbc.med.tohoku.ac.jp)

腎臓と低酸素

腎臓は酸素消費が多く，更に動静脈シャントのため酸素の取り込み効率が悪いため，低酸素状態になりやすい臓器であり，様々の要因によって引き起こされる尿細管間質の慢性低酸素が腎臓病の final common pathway として注目されている。（引用元：日児腎誌　Vol. 25 No. 2）

腎臓は生体が必要とする酸素の30％を消費する，非常に酸素需要の高い臓器となっている．このため，腎臓病のfinal common pathwayとして，尿細管間質の慢性低酸素状態が特に重要と考えられている．（第 113 回日本内科学会講演会結実する内科学の挑戦～今，そしてこれから～　平成28年4月17日（日）東京都・東京国際フォーラム　日本内科学会雑誌 105 巻 9 号）

腎が低酸素になりやすい理由としては，エネルギー需要が高いことに加え，尿細管周囲毛細血管網による酸素供給が血行動態の変化により影響を受けやすいことや，解剖学的な理由により動静脈酸素シャントが存在するため酸素の利用効率が悪いことがあげられる．（慢性低酸素状態の腎臓　244巻4号 2013年1月26日医学のあゆみ）

HIF刺激薬

EPO遺伝子の転写を促進する低酸素誘導因子（hypoxia-inducible factor: HIF）が同定され、さらにその上流の調節機構が解明されたことを背景に、「HIF活性化薬」としてPHD阻害薬が開発されました。　PHDはHIF （α鎖）を水酸化し、ユビキチン・プロテアソーム分解を導く酵素で、PHDの酵素活性を阻害するとHIFは安定化し、HIFを介する低酸素応答が誘導されます。（第4回（1）EPOから生まれた「HIF刺激薬」ここがすごい！執筆：田中哲洋（東京大学医学部附属病院）、監修：南学正臣（東京大学医学部附属病院）2018年8月15日　m3.com）

２０１９年ノーベル医学生理学賞はウィリアム・ケリン、ピーター・ラトクリフ、グレッグ・セメンザの3氏に

２０１９年ノーベル医学生理学賞はウィリアム・ケリン、ピーター・ラトクリフ、グレッグ・セメンザの3氏に贈られました。

The Nobel Assembly at Karolinska Institutet
has today decided to award
the 2019 Nobel Prize in Physiology or Medicine
jointly to
William G. Kaelin, Jr., Sir Peter J. Ratcliffe and Gregg L. Semenza.
for their discoveries of how cells sense and adapt to oxygen availability (PDF)

1 ２０１９年ノーベル医学生理学賞発表の瞬間
2 Sir Peter J. Ratcliffe
3
4 William G. Kaelin
5 Gregg Semenza
6 参考

２０１９年ノーベル医学生理学賞発表の瞬間

Announcement of the Nobel Prize in Physiology or Medicine 2019 Nobel Prize

Sir Peter J. Ratcliffe

ノーベル賞受賞直後のピーター・ラトクリフ氏の電話インタビュー

ピーター・ラトクリフ博士の講演動画。
Elucidation of oxygen sensing pathways in human and animal cells // Peter Ratcliffe 2018/09/28 The Physiological Society

William G. Kaelin

ウィリアム・ケリンのレクチャー動画。
Signaling Pathways in Cancer Symposium: William Kaelin 2016/08/11 KochInstituteMIT

Gregg Semenza

グレッグ・セメンザ（Gregg Semenza）が語る研究者の日常、研究はいかに進むか。

Gregg Semenza on the discovery of HIF-1

下の動画は、生い立ちから研究の話までのロング・インタビュー。
JCI’s Conversations with Giants in Medicine: Gregg Semenza 2016/11/02 Journal of Clinical Investigation

参考

Scientific Background How cells sense and adapt to oxygen availability (nobelprizemedicine.org)
ノーベル医学生理学賞に米、英の３氏「細胞の低酸素応答の仕組みの解明」(201/10/7(月) 18:42　毎日新聞　YAHOO!JAPAN) スウェーデンのカロリンスカ研究所は7日、2019年のノーベル医学生理学賞を米国とイギリスの3氏に授与すると発表した。受賞理由は「細胞の低酸素応答の仕組みの解明」。受賞が決まったのは、米ハーバード大のウィリアム・ケリン教授▽英オックスフォード大のピーター・ラトクリフ教授▽米ジョンズ・ホプキンズ大のグレッグ・セメンザ教授。

RECIST（レシスト）、mRECIST

1 RECIST
2 mRECISTとは

RECIST

固形がんの治療効果判定のための新ガイドライン (RECIST ガイドライン) ー改訂版 version 1.1ー日本語訳 JCOG 版 ver.1.0
固形がんの治療効果判定のための新ガイドライン（RECIST ガイドライン） ―日本語訳 JCOG版―

国際標準の治療効果判定規準である RECIST（Response Evaluation Criteria in Solid Tumors）guidelines がその妥当性ならびに従前のWHO 規準との再現性から、2000年に固形がん治療効果判定の国際標準として認知されている。RECIST は 2009 年
に EORTC(European Organization for Research and Treatment of Cancer)より改定された(E.A. Eisenhauer, et al. Eur J Cancer 2009;45:228-47)。(20－15 画像によるがんの診断、治療法選択、治療効果判定に関する研究)

mRECISTとは

2010年に Lencioni らによって提唱された modified RECIST（mRECIST）は，早期濃染部の径を測定することで肝癌治療効果判定に血流評価を加えた新しい基準である．（肝臓 53 巻 3 号１４７―154（2012））

一般的に固形癌の治療効果判定基準として WHO 基準を簡略化した Response Evaluation Criteria in Solid Tumors version1.1（RECIST1.1）が用いられている．しかしながら，肝細胞癌の治療においては，腫瘍壊死を治療効果として考えることが一般的であり，腫瘍壊死を効果判定基準に考慮されていない RECIST1.1 は問題があるとされている．一方，肝細胞癌の治療効果判定基準として腫瘍壊死を考慮に入れた modified（m）RECISTと日本肝癌研究会による肝癌治療直接効果判定基準 Response Evaluation Criteria in Cancer ofthe Liver（RECICL）も使用されている．mRECISTと RECICL でも 1 方向測定と 2 方向測定で明らかな違いがあり，その実用性，有用性については議論が分かれている．（肝臓 53 巻 6 号３４４―347（2012））

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19.
New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma. Riccardo Lencioni. Clinical Cancer Research 2013

Dr. Lencioni on Assessing Response to HCC Therapy 2018/09/16

複数のタイムポイントの測定値と開始点との個別の比較　多重比較の問題

例えば、薬物投与前後で差があるかどうかを調べるために経時変化を追う実験を行ったとします。どの時刻で開始時刻（薬物投与前）と差が出るかを調べるために、複数のデータポイントの各々と測定開始時とをペアワイズに比較することにして、２群間の比較でよく使うｔ－検定やWilcoxon検定を単純に適用してよいものでしょうか？たまに、そのような解析をした論文をたまに見かけることがありますが、これは非常に初歩的な、統計の誤用だと思われます。

データを入力するだけで統計ソフトが出力を返してくれるので、適用する検定方法が間違っていたとしても、P値だけは簡単に得ることができてしまいます。その結果、有意差がないデータに有意差を見出して論文報告してしまう危険があるので、要注意です。

1 経時データ（反復測定値）の統計学的解析における誤用の多さ
2 経時データ（反復測定値）の統計学的解析に関する現状
3 経時データ（反復測定値）の推奨される解析方法
4 参考

経時データ（反復測定値）の統計学的解析における誤用の多さ

鍼灸研究における統計誤用が多発しているため、この経時測定データの解析法について調べても、ほとんど誤用といってよい（経時測定データの解析法　七堂利幸）

多群間の平均値の比較において，その目的に応じた多重比較法を用いることが一般化してきた．しかしながら，経時データのように複数の測定時点がある場合に，時点ごとに多重比較法を繰り返し適用することは，いずれかの時点で有意な差が出やすくなる「時点の多重性の問題」が新たに生じてしまう．（引用元：日薬理誌133，325～331（2009））

比較試験では各被験者について経時的に種々の評価や測定がなされ、経時的な薬効差の検討が行われる。この際の検定に当っては、薬剤群ごとに処置開始時点とそれ以降の評価時点とに対応のある場合の検定を繰返したり、各時点とに２群間での対応のない場合の検定を繰しがちであるが、それでは第１種の過誤の確率の増大する。（引用元：臨床試験の統計解析に関するガイドライン　平成４年３月４日）

経時データ（反復測定値）の統計学的解析に関する現状

一般に用量時間反型データに繁用されている統計解析は2種類ある．一っは「輪切り」検定であり，他の一っは2元配置分散分析である．（薬理試験における統計解析のQ&A 反復測定データの解析法への一提案吉村功、大森崇　日薬理誌110、333～340（1997））

経時データ（反復測定値）の推奨される解析方法

１３．経時的比較 　

比較試験では各被験者について経時的に種々の評価や測定がなされ、経時的な薬効差の検討が行われる。この際の検定に当っては、薬剤群ごとに処置開始時点とそれ以降の評価時点とに対応のある場合の検定を繰返したり、各時点とに２群間での対応のない場合の検定を繰しがちであるが、それでは第１種の過誤の確率の増大する。このようなデータの場合には時点毎の比較ではなく、トレンドやプロフィルを比較するための特別な手法が必要である。

（引用元：臨床試験の統計解析に関するガイドライン 　平成４年３月４日 　http://home.att.ne.jp/red/akihiro/Old_stat_guideline_Japanese.pdf）

臨床試験のための統計的原則 医薬審第1047号平成10年11月30日各都道府県衛生主管部(局)長殿厚生省医薬安全局審査管理課長　本ガイドラインは、本通知の日以降施行し、これに伴い、「臨床試験の統計解析に関するガイドライン(平成4年3月4日薬新薬第20号)」(以下「旧ガイドライン」という。)は廃止する。

慢性疾患のための治療の研究で、経時的に機能の状態を評価する場合も、主要変数の選択に関して別の問題が生じる。可能な対処法としては、観察期間の最初と最後になされた評価の比較、全期間を通じたすべての評価から求めた傾きの比較、定めた閾値を超える若しくは下回る被験者の割合の比較、又は繰り返し測定データのための方法に基づいた比較といった多くのものがある。（引用元：2.2.2 主要変数と副次変数　臨床試験のための統計的原則医薬審第1047号平成10年11月30日）　＊太字強調は当サイト

下は、なんでもかんでも検定して有意差を出せばよいと思っている人に対する警告。

では両者に共通な問題点は何だろうか．それは実験で知りたいことが反応の時間曲線であり，それが用量によってどうわるかであるのに，それに答えられるはずのない「検定という形式」の統計解析を行っていることである．ここで採用している検定という形式は，「反応が用量によって変わらない」あるいは，「反応が時間によって変わらない」という仮説が，実際に測定したデータから否定できるかどうかを判定するものである．だからそれによって得られる結論は，「反応が用量によって変わるところがあるかどうか」，あるいは「反応が時間によって変わるところがあるかどうか」ということでしかない．（薬理試験における統計解析のQ&A 反復測定データの解析法への一提案吉村功、大森崇　日薬理誌110、333～340（1997））＊太字下線強調は当サイト

参考

薬理試験における統計解析のQ&A　反復測定データの解析法への一提案　吉村功、大森崇　日薬理誌110、333～340（1997）一般に用量時間反型データに繁用されている統計解析は2種類ある．一っは「輪切り定」であり，他の一っは2元配置分散分析である．
改訂増補版：統計検定を理解せずに使っている人のためにIII 池田郁男東北大学未来科学技術共同研究センター Published: 2019-10-01 © 2019 公益社団法人日本農芸化学会　”たとえば，0分と5分後の2点の比較であれば，paired t testを行うことができる．しかし，ここでは4点あるので，paired t testは使えない．分散分析は何らかの変化が起こったことがわかるので，この例では有意差が得られれば，統計的に有意に増加が起こったと判断される．”
保健・医療研究の進め方入門 —R と EZR を用いて— （保健学共通特講 IV, VIII テキスト Rev. 0.9.9.4）神戸大学大学院保健学研究科教授：中澤港 2019 年 7 月 24 日　第 12 章反復測定データの解析
薬理学研究における経時データ解析の考え方─血圧降下試験事例による解説─　高橋行雄　日薬理誌（Folia Pharmacol. Jpn.）133，325～331（2009）
経時データの多重比較法 岸本淳司 (ＳＡＳ／慶應義塾大学／東京大学)
反復測定分散分析 Repeated-Measure Analysis of Variance （ANOVA） オーエムエス出版
多群・経時データの解析と多重比較　医学統計セミナーアドバンスコース　下川敏雄和歌⼭県⽴医科⼤学臨床研究センター（スライドPDF）
経時的繰り返し測定データの解析　医学統計勉強会東北大学病院循環器内科・東北大学臨床研究推進センター共催東北大学大学院医学系研究科EBM開発学寄附講座宮田敏　2013/10/31 第6回
Bretz et al. (2011). Multiple Comparisons Using R.
基本的な回帰モデル • 混合モデル • 「混合モデル」手法の別例 • 反復測定の例　JMP13.2 オンラインマニュアル
臨床試験における多重性の諸問題 計量生物学 Vol. 36, Special Issue, S 87–S 98 (2015) 寒水孝司東京理科大学工学部経営工学科
臨床試験における統計的諸問題 明星大学・理工学部広津千尋数理解析研究所講究録 1273 巻 2002 年 78-86
経時測定データの解析法ーその文献とソフトの紹介ー　七堂利幸　鍼灸研究における統計御用が多発しているため、この経時測定データの解析法について調べても、ほとんど御用といってよい
生物医学研究文献の誰でも見つけられる20の統計学的誤り Tom Lang
ウィルコクソンの順位和検定とは？t検定との違いは？（一番優しい、医薬品開発に必要な統計学の教本）
連載第 2 回医学データの統計解析の基本 2 つの平均の比較　朝倉こう子・濱﨑俊光　t検定は日常的に利用されるが、実際のデータ解析でのt検定の利用について、｢観測値数が極端に少ない場合、t検定は適用可能か（観測値数がどの程度あればt検定が適用可能か）｣、｢観測値の正規性の検定をしたところ、正規分布に従わないとの結果が得られたから、t検定の代用としてWilcoxonの順位和検定（あるいはMann-WhitneyのU検定）を用いたが、この判断に間違いないか｣、｢統計手法の手順書には、2つの群でデータの分散の大きさが異なる場合には、t 検定の代用としてWelchのt検定を適用すべきとの記載があったが、2つの群の分散が異ならない場合にもWelchのt検定は適用可能か｣といった疑問をよく耳にする。
毒性試験および生物を扱う研究者のための統計解析 小林克己

細胞傷害性T細胞（キラーT細胞）とは

1 細胞傷害性T細胞とは
2 細胞傷害性T細胞の呼称
3 細胞傷害性T細胞の分化
4 細胞傷害性T細胞の活性化
5 細胞傷害性T細胞の活性化のしくみ
6 共刺激
7 殺すべき細胞をキラーT細胞が認識する仕組み
8 キラーT細胞が相手の細胞を殺す仕組み

細胞傷害性T細胞とは

細胞傷害性T細胞(cytotoxic T lymphocyte; CTL)は、リンパ球T細胞の一種で、宿主にとって異物である細胞すなわち、移植細胞、ウイルス感染細胞、癌細胞などを認識して破壊する。（参照：ウィキペディア）

細胞傷害性T細胞の呼称

細胞傷害性T細胞は、キラーT細胞、CD8陽性T細胞、CD8+T細胞などとも呼ばれる。（参照：ウィキペディア）

細胞傷害性T細胞の分化

未分化のT細胞は、CD4分子と、CD8分子の両方を発現している（ダブルポジティブ）。T細胞が成熟するにつれ、分化をしていき、CD4とCD8のどちらか一方しか発現しなくなる（シングルポジティブ）。CD8分子を発現しているT細胞がキラーT細胞へと分化する。他方、CD4分子を発現しているT細胞はヘルパーT細胞へ分化する。（参照：ウィキペディア）

細胞傷害性T細胞の活性化

抗原刺激を受ける前のキラーT細胞は、細胞傷害活性を持たないナイーブCD8陽性T細胞であるが、抗原刺激を受けを受けて活性化し、細胞傷害活性を持つようになる。（参照：ウィキペディア）

細胞傷害性T細胞の活性化のしくみ

抗原提示細胞(APC)が、ナイーブCD8陽性T細胞に対して、異物の「抗原ペプチド」（ウイルスや細菌などの抗原を分解したペプチドのこと）クラスI主要組織適合抗原(MHC-class I）と共に提示する。ナイーブCD8陽性T細胞は、T細胞受容体(TCR; T cell receptor)を介してそれを認識する。これと同時に「共刺激分子」からのシグナルが入っていると（後述）、ナイーブCD8陽性T細胞はこの異物の抗原ペプチドを提示する細胞に特異的な細胞傷害活性を持つようになる。（参照：ウィキペディア）

共刺激

T細胞活性化におけるCD137受容体の役割 (Immuno-Oncoloy)
T細胞の活性化 (Immuno-Oncology)

殺すべき細胞をキラーT細胞が認識する仕組み

ほとんどの細胞は、細胞表面にＭＨＣ（主要組織適合性複合体）クラスＩという分子を持っていて、普段はＭＨＣクラスＩの上に自分自身の抗原をを乗せて細胞表面に提示している。この「目印」のおかげで、キラーＴ細胞からの攻撃を受けずにすんでいる。しかし、細胞が病原体に感染すると、ＭＨＣクラスＩの上に（自分自身の抗原ではなく）病原体由来の抗原を乗せて細胞表面に提示する。これが目印となり、病原体に感染した細胞はキラーＴ細胞に殺傷される。（参照：理研プレスリリース解説　平成28年）

病原体や癌細胞の抗原がT細胞に認識される様子をまとめた下の図がわかりやすい。

（出典：京府医大誌 126（6），377～389，2017）

キラーT細胞が相手の細胞を殺す仕組み

CTLは細胞傷害物質であるパーフォリン、グランザイム、 TNF (tumor necrosis factor)などを放出したり、ターゲット細胞のFasを刺激してアポトーシスに陥らせることで異物を攻撃する。（参照：ウィキペディア）

キラー細胞が標的細胞を認識すると細胞間隙にパーフォリンやグランザイムBなどを含む顆粒成分が放出される．また，キラー細胞表面上に発現したFasL， TRAIL，TNF-α，TWEAKといったTNFファミリー分子が標的細胞上に発現している各々の対応するレセプターに結合することによって，標的細胞に細胞死が誘導される．（Inflammation and Regeneration Vol.23 No.3 May 2003　PDF）

心臓足首血管指数　Cardio Ankle Vascular Index – CAVI

CAVIとは

　CAVI（キャビィ）は大動脈を含む「心臓（Cardio）から足首（Ankle）まで」の動脈（Vascular）の硬さを反映する指標（Index）で、動脈硬化が進行するほど高い値となります。（CAVI（Cardio Ankle Vascular Index）　動脈の硬さの指標 CAVI　フクダ電子）

CAVI Video 2017/10/26 CareFor U.

参考

K.Hayashi, H.Handa, S.Nagasawa, A.Okumura, K.Moritake Stiffness and elastic behavior of human intracranial and extracranial arteries. Journal of Biomechanics Volume 13, Issue 2, 1980, Pages 175-179, , 181-184 Free abstract

科研費は基盤Aか、手堅くBか、審査区分は？

1 審査区分導入の余波
2 基盤（S）、基盤（A）と基盤（B）の審査のされ方の違いを理解する
3 その審査区分におけるライバルの強さを把握する
4 ライバルチェックを実際にやってみよう
5 審査委員の顔ぶれを知る
6 応募件数を知る
7 審査区分を選ぶときの考え方
8 基盤研究（B）か基盤研究（C）か
9 計画調書を人に読んでもらう

審査区分導入の余波

2018年度（平成30年度）科研費（2017年秋の申請）から、審査のための領域の分け方が変更されました。それまでお馴染みだった「細目」がなくなり、「小区分」という呼び名に代わり、分け方や大きさも変わりました。

平成 30 年度助成（平成 29 年９月公募予定）からの審査は、「小区分・中区分・大区分」で構成される新しい審査区分で行う。それに伴い、現行の「系・分野・分科・細目表」は廃止し、新しく「審査区分表」を設定する。（科研費審査システム改革２０１８）

基盤（C)は小区分の中での相対評価となり、小区分の数は細目数の7割程度なので、やや分野が広がった程度といえます。それに対して、基盤（A）は中区分、基盤（S）にいたっては大区分という、かなり大雑把なわけ方の中での審査となります。

審査区分表（大区分、中区分、小区分）（JSPSのサイト）

このため、狭い研究分野でしっかりとした足場を築いてきた研究者の場合、これまではコンスタントに基盤研究で大型予算が獲得できていたのに、科研費審査システム改革以降は、自分の足場がどこ（の審査区分）にあるのかを見失ってしまい、思うように大型予算がとれなくなってしまったということもあるようです。場合によっては、基盤（A）をあきらめて基盤（B）を狙いにいこうかと悩むこともあるでしょう。

基盤（S）、基盤（A）と基盤（B）の審査のされ方の違いを理解する

基盤S,A,Bのどこに出すかを悩む前に、まずはそれらがどのように審査されるのかという審査の仕組みを理解する必要があります。

基盤研究（Ｓ）　　　　審査区分：大区分 審査方式：総合審査（書面審査及び合議審査）ヒアリング審査を実施
基盤研究（Ａ）（一般）審査区分：中区分 審査方式：総合審査（書面審査及び合議審査）　審査委員の人数：6人～8人
基盤研究（Ｂ）（一般）審査区分：小区分 審査方式：２段階書面審査　審査委員の人数：6人
基盤研究（Ｃ）（一般）審査区分：小区分審査方式：２段階書面審査　審査委員の人数：4人

もう少し詳しい説明は、以下の通り。

「基盤研究（Ｓ）」は、研究計画調書及び専門分野が近い研究者が作成する審査意見書（国内の研究機関に所属する審査意見書作成者、３名程度が作成）等に基づき、大区分ごとに、６人の審査委員が全ての応募研究課題について、書面審査。その後、書面審査と同一の審査委員が合議審査の場で各応募研究課題について幅広い視点から議論により審査を行い、ヒアリング対象課題を選定し、ヒアリング審査を行います。（総合審査）
「基盤研究（Ａ）」（応募区分「一般」）　中区分ごとに、６人～８人の審査委員が、全ての応募研究課題について、書面審査を行った上で、同一の審査委員が合議審査審査。（「総合審査」）
「基盤研究（Ｂ・Ｃ）」（応募区分「一般」）及び「若手研究」は、小区分ごとに、「基盤研究（Ｂ）」は６人、「基盤研究（Ｃ）」「若手研究」は４人の審査委員が２段階にわたり書面審査。

（参考：平成３１年度科学研究費助成事業　公募要項　PDF）

こうしてみると、基盤Aと基盤Bは単に金額の大きさが異なるだけでなく、審査のされ方が大きく異なります。基盤Bと基盤Cの方が、審査のされ方という点では近いのです。

その審査区分におけるライバルの強さを把握する

例えば、科研費改革の前の細目の時代に分子生物学や遺伝学をやっていた人は、今はどこに出せばよいのでしょうか？大区分や中区分を選ぶ際に、その中の小区分の名称が一つの手がかりになります。

大区分G

中区分43分子レベルから細胞レベルの生物学およびその関連分野

小区分43010 分子生物学関連（染色体機能、クロマチン、エピジェネティクス、遺伝情報の維持、遺伝情報の継承、遺伝情報の再編、遺伝情報の発現、タンパク質の機能調節、分子遺伝、など）

小区分43050ゲノム生物学関連 （ゲノム構造、ゲノム機能、ゲノム多様性、ゲノム分子進化、ゲノム修復維持、トランスオミックス、エピゲノム、遺伝子資源、ゲノム動態、など）

中区分44：細胞レベルから個体レベルの生物学およびその関連分野

小区分44010 細胞生物学関連（細胞骨格、タンパク質分解、オルガネラの動態、核の構造機能、細胞外マトリックス、シグナル伝達、細胞周期、細胞運動、細胞間相互作用、細胞遺伝、など）

小区分44020 発生生物学関連 （細胞分化、幹細胞、再生、胚葉形成、形態形成、器官形成、受精、生殖細胞、遺伝子発現調節、発生遺伝、進化発生、など分解、オルガネラの動態、核の構造機能、細胞外マトリックス、シグナル伝達、細胞周期、細胞運動、細胞間相互作用、細胞遺伝、など）

中区分 45：個体レベルから集団レベルの生物学と人類学およびその関連分野

小区分45010 遺伝学関連 （遺伝機構、分子遺伝、細胞遺伝、集団遺伝、進化遺伝、発生遺伝、行動遺伝、遺伝的多様性、など）

ざっと見ただけでも、３つの中区分の中に遺伝学や分子生物学っぽい内容が含まれています。こうなると、どこにでも当てはまりそうという状態になりそうです。各々の小区分でどんな人が審査委員になっているのかがわかればよいのですが、審査委員氏名が公表されるのは2年後です。ただし、小区分名と以前の細目名との対応がつく場合は、その細目での過去の審査委員を調べることは可能でしょう。

ライバルチェックを実際にやってみよう

科研費の審査が区分ごとの相対評価である以上、ライバルが強い区分に出すのは避けたいものです。基盤Aなどはどんな先生方が獲得されているのでしょうか？KAKENデータベースを使えば直ちにわかります。例えば、中区分44：細胞レベルから個体レベルの生物学およびその関連分野で2019年度に基盤（A）を採択されたものは、中区分名をキーワードに入れて検索すると、9件しかないことがわかります。

研究課題名	研究代表者
“記憶の局所フィードバック仮説”ーその中枢単一同定ニューロンでの検証	吉原基二郎国立研究開発法人情報通信研究機構, 未来ICT研究所フロンティア創造総合研究室, 総括研究員 (80222397)
プロテアソームの細胞生理学	田中啓二公益財団法人東京都医学総合研究所, 生体分子先端研究分野, 理事長 (10108871)
シグナルと力のゆらぎが上皮組織の可塑性を支配するしくみ	林茂生国立研究開発法人理化学研究所, 生命機能科学研究センター, チームリーダー (60183092)
抑制と抗抑制によるエピゲノム分化機構の解明と操作	角谷徹仁国立遺伝学研究所, 遺伝メカニズム研究系, 教授 (20332174)
細胞が材料を組み立てて体を「建築」する仕組みの解明	近藤滋大阪大学, 生命機能研究科, 教授 (10252503)
細胞増殖因子情報伝達系の活性波による細胞集団移動制御機構	松田道行京都大学, 生命科学研究科, 教授 (10199812)
合成生物学のアプローチを導入したプロトン駆動力ネットワークの解明	鹿内利治京都大学, 理学研究科, 教授 (70273852)
気孔の発生とパターン形成を制御する新奇メカニズムに合成化学で切込む	鳥居啓子名古屋大学, トランスフォーマティブ生命分子研究所, 客員教授 (60506103)
脊椎動物の季節適応機構の解明	吉村崇名古屋大学, 生命農学研究科(WPI), 教授 (40291413)

こうしてみると基盤（A）で採択されるのは、全国的に名の知れた研究者ばかりということがわかります。試しに2018年度の中区分44：細胞レベルから個体レベルの生物学およびその関連分野での基盤（A）採択者も見てみると、

研究課題名	研究代表者
哺乳類の複雑脳形成プログラムの解明	松崎文雄国立研究開発法人理化学研究所, 生命機能科学研究センター, チームリーダー (10173824)
小胞体における活性酸素除去に関わる新たな分子機構の解明	永田和宏京都産業大学, 生命科学部, 教授 (50127114)
植物の光受容体フィトクロムによる転写開始点制御の分子機構解明	松下智直九州大学, 農学研究院, 准教授 (20464399)
幹細胞における細胞周期制御と代謝系との連関に関する基盤的研究	中山敬一九州大学, 生体防御医学研究所, 主幹教授 (80291508)
上皮バリアの構築と機能を制御するタイトジャンクション・アピカル複合体の解析	月田早智子大阪大学, 生命機能研究科, 教授 (00188517)
造血幹細胞を維持する微小環境（ニッチ）の形成と作用の分子機構の解明	長澤丘司大阪大学, 生命機能研究科, 教授 (80281690)
細胞間情報を担う糖鎖AMORの発見に基づく植物糖鎖シグナリングの解明	東山哲也東京大学, 大学院理学系研究科(理学部), 教授 (00313205)
植物の浸透圧ストレスに対する感知システムと初期応答の分子機構の解明	篠崎和子東京大学, 大学院農学生命科学研究科(農学部), 教授 (30221295)
浸透圧ストレスの受容・認識から応答に至る分子機構の解明	一條秀憲東京大学, 大学院薬学系研究科(薬学部), 教授 (00242206)
細胞競合と接触阻害を統合的に制御する分子メカニズムの解明	藤田恭之北海道大学, 遺伝子病制御研究所, 教授 (50580974)

やはり、メジャーな大学に所属する著名な研究者ばかりでしかもたったの10件しか採択されていません。厳しい戦いですね。全然その分野のことを知らない自分のような人間が見ても、面白そうな採択課題名が並んでいます。審査委員の専門分野が多岐にわたることを考えれば、広く興味を引くように、研究課題名にも工夫を凝らす必要がありそうです。

さて、基盤研究（A）のレベルの高さがわかったので、基盤（B）がそれに比べてどうなのかも見てみたいと思います。基盤研究（B）でのライバルのレベルを知るには、自分が出してみようと思っている小区分名を入れて同様の検索を行ってみるとよいでしょう。例えば、この同じ中区分の中の一つの小区分44050 動物生理化学、生理学および行動学関連で検索をかけてみると、2018年度、2019年度の採択課題は、

研究課題名	研究期間 (年度)	研究代表者
昼行性生物と夜行性生物における概日光受容体メラノプシンの機能解析	2019-04-01 – 2022-03-31	羽鳥恵慶應義塾大学, 医学部(信濃町), 特任准教授 (90590472)
概日時計細胞間の接続様式とその役割	2019-04-01 – 2023-03-31	吉井大志岡山大学, 自然科学研究科, 准教授 (50611357)
嗅覚受容体クラス選択の遺伝学的操作による嗅覚行動の制御とその分子基盤の解明	2019-04-01 – 2023-03-31	廣田順二東京工業大学, バイオ研究基盤支援総合センター, 准教授 (60405339)
眠気の統合センシングシステムの理解	2019-04-01 – 2023-03-31	Liu Qinghua 筑波大学, 国際統合睡眠医科学研究機構, 教授 (90723792)
動物変態の進行を協調的に制御する神経伝達・ホルモン調節機構の解明	2019-04-01 – 2023-03-31	笹倉靖徳筑波大学, 生命環境系, 教授 (10400649)
微小脳における習慣記憶形成とその神経基盤の解明	2019-04-01 – 2022-03-31	水波誠北海道大学, 理学研究院, 教授 (30174030)
機能未知光受容タンパク質に着目した脊椎動物の脳内光受容とその多様性の解明	2018-04-01 – 2022-03-31	小柳光正大阪市立大学, 大学院理学研究科, 准教授 (30379276)
ショウジョウバエの睡眠覚醒制御機構の総合的研究	2018-04-01 – 2021-03-31	粂和彦名古屋市立大学, 大学院薬学研究科, 教授 (30251218)
昆虫概日時計の複眼依存性光同調の分子機構	2018-04-01 – 2021-03-31	富岡憲治岡山大学, 自然科学研究科, 教授 (30136163)
メダカの顔認知の分子神経基盤の解明	2018-04-01 – 2021-03-31	竹内秀明岡山大学, 自然科学研究科, 准教授 (00376534)
昆虫の光周性の分子・神経機構：概日時計と日長測定	2018-04-01 – 2021-03-31	沼田英治京都大学, 理学研究科, 教授 (70172749)
概日リズムの時刻情報変換に関わる神経回路動作原理の理解	2018-04-01 – 2021-03-31	小野大輔名古屋大学, 環境医学研究所, 助教 (30634224)
ショウジョウバエにおける求愛定位行動解発の神経回路メカニズム	2018-04-01 – 2023-03-31	古波津創国立研究開発法人情報通信研究機構, 未来ICT研究所フロンティア創造総合研究室, 研究員 (40571930)

となっています。基盤（B）採択者も業績のある研究者ばかりで、やはり熾烈な戦いのようです。採択件数も少ないですし、手堅く基盤（B）などとはとても言えない厳しさであることがわかりました。

審査委員の顔ぶれを知る

ライバルチェックと並んでもう一つ重要なことが、いったい誰が審査しているのかを知ることです。科研費はピアレビューのシステムですから、審査委員も自分の友達、知人、同業者です。JSPSのウェブサイトに、2年たったら審査委員の氏名が公開されますので、2年前の科研費であれば自分の計画調書を誰が読んで採択してくれたのか、あるいは不採択にしてくれたのかがわかるわけです。

審査委員名簿　https://www.jsps.go.jp/j-grantsinaid/14_kouho/meibo.html

応募件数を知る

もう一つ気になるのが、自分が出す研究種目、審査区分にどれくらいの応募件数があって、採択率はどれくらいなのかということです。このような個別のデータもJSPSのウェブサイトに公開されています。

https://www.jsps.go.jp/j-grantsinaid/27_kdata/index.html　

審査区分別配分状況（平成31年2月14日更新）　平成30年度（2018年度）　などが参考になります。

こういった、自分が戦う場所を知ることが、科研費を勝ち取るためには必要です。やみくもに計画調書を書いて出しても、実は土俵にすら上がれていなかったということになりかねません。

審査区分を選ぶときの考え方

どの審査区分に出すかの決断は難しいものです。研究テーマがマッチしており、なおかつ、その審査区分で採択されている人たちの業績などを調べて、自分が勝負を挑んだときに業績的に勝てる相手かどうかを見極めることが必要でしょう。その審査区分の中での相対評価で採択・不採択が決まるわけですから。自分の研究を高く評価してくれる審査委員がどの審査区分にいるのかを調べることもまた重要です。普段からいろいろな学会で発表していれば、自分の研究をどういう人たちが面白がってくれるかがわかります。自分の研究を面白いと言ってくれた研究者が審査委員をやっている審査区分を選んで出せば、採択される可能性は高まるでしょう。

基盤研究（B）か基盤研究（C）か

世の中には基盤（A)に出すか基盤（B)にするかで悩む研究者がいるのと同様に、基盤研究（B）と基盤研究（C）との間で悩んでいる研究者もいます。ここでも、考え方は同様です。しっかりと、自分が出そうとしている審査区分のライバルたちの業績を調べ上げましょう。勝てない人たちに喧嘩を売っても、勝てません。自分が買いたい測定装置が高価で、基盤（C)の金額を超えてしまうので基盤（B)に出そうなどとナイーブに考えたら、痛い目に合います。基盤（C)と基盤（B）との間のギャップは、単に申請できる金額の上限の差ではありません。採択される研究者の業績の差は、それよりもはるかに大きいのです。

そのへんの事情は、科研費の教科書を書かれている児島将康先生のウェブ記事（↓）が参考になります。

実際に審査した経験からいうと，基盤研究（B）と基盤研究（C）の間には，かなりのレベルの違いがある．両者の採択率はほとんど変わらないが，基盤研究（B）になると優れた業績（ということはインパクトファクターの高い雑誌に掲載された論文）をもっていて，これまでにも基盤研究（B）以上の研究費を獲得している研究者が多く，かなりハイレベルの競争になる．一方，基盤研究（C）になるとある程度の発表論文さえあれば十分に採択される．本来なら必要とする研究費の額に応じて基盤研究（A），基盤研究（B），基盤研究（C）のなかのどれに応募するか選択するのがよいのだろうが，実際には自分の研究レベルを考慮して選択するのがよい．（第1回応募種目の選び方　科研費獲得のための応募戦略　Smart Lab Life　羊土社）＊太字下線は当サイト

計画調書を人に読んでもらう

アドバイスをくれる人みんなが口を酸っぱくして言っていることなのに、それを聞いたみんながちっともやらないこと、それが「計画調書を人に読んでもらう」ということです。なぜ一人で書いてそのまま出してしうのでしょうか？「俺は今まで一人でやってきたんだ。だから一人でできる！」という自信でしょうか？「大型の科研費をとったこともないやつに何がわかる？！」というプライドでしょうか。「自分の計画調書を人に読まれるのはなんとなくいや。」という恥じらいでしょうか。サイコロジーはよくわかりませんが、書いたものを他人に見せられるだけのオープンマインドな人のほうが、採択される可能性が高いのは当たり前の話です。

科研費改革2018で審査のルール（区分）が変わりました。申請者はこの変化に対応する必要があります。基盤Aは、より広い分野の研究者が審査することになったため、今までと同じように書いても理解されない恐れがあります。ですから、書き上げた計画調書をできるだけいろいろな人に読んでもらい、研究の意義や目的が理解しやすいかどうかを聞いてみたほうがよいと思います。

植物学の大御所に、私はいつも科研費申請書を学生に読んでもらって改訂していると申し上げたところ、「私はいつも妻に読んでもらって、専門家以外にもわかりやすい表現を工夫している」と返された。採択率が高い研究者は、それだけの努力をされているのだと知って、納得した。

— Tetsukazu Yahara (@TetYahara) April 2, 2018

科研費獲得の方法とコツ改訂第７版
科研費採択される3要素第2版
いかにして研究費を獲得するか